Literature DB >> 24106341

Lipid-induced toxicity stimulates hepatocytes to release angiogenic microparticles that require Vanin-1 for uptake by endothelial cells.

Davide Povero1, Akiko Eguchi, Ingrid R Niesman, Nektaria Andronikou, Xavier de Mollerat du Jeu, Anny Mulya, Michael Berk, Milos Lazic, Samjana Thapaliya, Maurizio Parola, Hemal H Patel, Ariel E Feldstein.   

Abstract

Angiogenesis is a key pathological feature of experimental and human steatohepatitis, a common chronic liver disease that is associated with obesity. We demonstrated that hepatocytes generated a type of membrane-bound vesicle, microparticles, in response to conditions that mimicked the lipid accumulation that occurs in the liver in some forms of steatohepatitis and that these microparticles promoted angiogenesis. When applied to an endothelial cell line, medium conditioned by murine hepatocytes or a human hepatocyte cell line exposed to saturated free fatty acids induced migration and tube formation, two processes required for angiogenesis. Medium from hepatocytes in which caspase 3 was inhibited or medium in which the microparticles were removed by ultracentrifugation lacked proangiogenic activity. Isolated hepatocyte-derived microparticles induced migration and tube formation of an endothelial cell line in vitro and angiogenesis in mice, processes that depended on internalization of microparticles. Microparticle internalization required the interaction of the ectoenzyme Vanin-1 (VNN1), an abundant surface protein on the microparticles, with lipid raft domains of endothelial cells. Large quantities of hepatocyte-derived microparticles were detected in the blood of mice with diet-induced steatohepatitis, and microparticle quantity correlated with disease severity. Genetic ablation of caspase 3 or RNA interference directed against VNN1 protected mice from steatohepatitis-induced pathological angiogenesis in the liver and resulted in a loss of the proangiogenic effects of microparticles. Our data identify hepatocyte-derived microparticles as critical signals that contribute to angiogenesis and liver damage in steatohepatitis and suggest a therapeutic target for this condition.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24106341      PMCID: PMC4016801          DOI: 10.1126/scisignal.2004512

Source DB:  PubMed          Journal:  Sci Signal        ISSN: 1945-0877            Impact factor:   8.192


  63 in total

1.  Direct analysis and identification of proteins in mixtures by LC/MS/MS and database searching at the low-femtomole level.

Authors:  A L McCormack; D M Schieltz; B Goode; S Yang; G Barnes; D Drubin; J R Yates
Journal:  Anal Chem       Date:  1997-02-15       Impact factor: 6.986

2.  Regulation of late G1/S phase transition and APC Cdh1 by reactive oxygen species.

Authors:  Courtney G Havens; Alan Ho; Naohisa Yoshioka; Steven F Dowdy
Journal:  Mol Cell Biol       Date:  2006-06       Impact factor: 4.272

Review 3.  Microparticles, vascular function, and atherothrombosis.

Authors:  Pierre-Emmanuel Rautou; Anne-Clémence Vion; Nicolas Amabile; Gilles Chironi; Alain Simon; Alain Tedgui; Chantal M Boulanger
Journal:  Circ Res       Date:  2011-08-19       Impact factor: 17.367

Review 4.  Nonalcoholic fatty liver disease in the pediatric population: a review.

Authors:  Anna Wieckowska; Ariel E Feldstein
Journal:  Curr Opin Pediatr       Date:  2005-10       Impact factor: 2.856

5.  Use of cyclodextrins for manipulating cellular cholesterol content.

Authors:  A E Christian; M P Haynes; M C Phillips; G H Rothblat
Journal:  J Lipid Res       Date:  1997-11       Impact factor: 5.922

6.  Cyclin-dependent kinase 5 regulates endothelial cell migration and angiogenesis.

Authors:  Johanna Liebl; Sabine B Weitensteiner; György Vereb; Lili Takács; Robert Fürst; Angelika M Vollmar; Stefan Zahler
Journal:  J Biol Chem       Date:  2010-09-07       Impact factor: 5.157

7.  Neovascularization and oxidative stress in the progression of non-alcoholic steatohepatitis.

Authors:  Mitsuteru Kitade; Hitoshi Yoshiji; Hideyuki Kojima; Yasuhide Ikenaka; Ryuichi Noguchi; Kosuke Kaji; Junichi Yoshii; Koji Yanase; Tadashi Namisaki; Masaharu Yamazaki; Tatsuhiro Tsujimoto; Kei Moriya; Hideto Kawaratani; Takemi Akahane; Hiroshi Fukui
Journal:  Mol Med Rep       Date:  2008 Jul-Aug       Impact factor: 2.952

8.  Characterization and comprehensive proteome profiling of exosomes secreted by hepatocytes.

Authors:  Javier Conde-Vancells; Eva Rodriguez-Suarez; Nieves Embade; David Gil; Rune Matthiesen; Mikel Valle; Felix Elortza; Shelly C Lu; Jose M Mato; Juan M Falcon-Perez
Journal:  J Proteome Res       Date:  2008-12       Impact factor: 4.466

Review 9.  Lipid rafts and caveolae and their role in compartmentation of redox signaling.

Authors:  Hemal H Patel; Paul A Insel
Journal:  Antioxid Redox Signal       Date:  2009-06       Impact factor: 8.401

Review 10.  Endocytosis of glycosylphosphatidylinositol-anchored proteins.

Authors:  Shaheen E Lakhan; Shefali Sabharanjak; Ananya De
Journal:  J Biomed Sci       Date:  2009-10-15       Impact factor: 8.410

View more
  81 in total

Review 1.  Extracellular vesicles in liver disease and potential as biomarkers and therapeutic targets.

Authors:  Gyongyi Szabo; Fatemeh Momen-Heravi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-06-21       Impact factor: 46.802

2.  Shedding Perspective on Extracellular Vesicle Biology in Diabetes and Associated Metabolic Syndromes.

Authors:  Naureen Javeed
Journal:  Endocrinology       Date:  2019-02-01       Impact factor: 4.736

3.  Extracellular vesicles released by hepatocytes from gastric infusion model of alcoholic liver disease contain a MicroRNA barcode that can be detected in blood.

Authors:  Akiko Eguchi; Raul G Lazaro; Jiaohong Wang; Jihoon Kim; Davide Povero; Brandon Willliams; Samuel B Ho; Peter Stärkel; Bernd Schnabl; Lucila Ohno-Machado; Hidekazu Tsukamoto; Ariel E Feldstein
Journal:  Hepatology       Date:  2016-11-10       Impact factor: 17.425

Review 4.  Extracellular vesicles as potential biomarkers for alcohol- and drug-induced liver injury and their therapeutic applications.

Authors:  Young-Eun Cho; Byoung-Joon Song; Mohammed Akbar; Moon-Chang Baek
Journal:  Pharmacol Ther       Date:  2018-04-03       Impact factor: 12.310

Review 5.  Origins of Portal Hypertension in Nonalcoholic Fatty Liver Disease.

Authors:  Gyorgy Baffy
Journal:  Dig Dis Sci       Date:  2018-01-22       Impact factor: 3.199

Review 6.  Non-alcoholic steatohepatitis pathogenesis: sublethal hepatocyte injury as a driver of liver inflammation.

Authors:  Samar H Ibrahim; Petra Hirsova; Gregory J Gores
Journal:  Gut       Date:  2018-01-24       Impact factor: 23.059

7.  Emricasan, a pan-caspase inhibitor, improves survival and portal hypertension in a murine model of common bile-duct ligation.

Authors:  Akiko Eguchi; Yukinori Koyama; Alexander Wree; Casey D Johnson; Ryota Nakamura; Davide Povero; David Kneiber; Masahiko Tameda; Patricia Contreras; Al Spada; Ariel E Feldstein
Journal:  J Mol Med (Berl)       Date:  2018-05-05       Impact factor: 4.599

8.  Decoding the Role of Extracellular Vesicles in Liver Diseases.

Authors:  Fengyan Deng; Nancy Magee; Yuxia Zhang
Journal:  Liver Res       Date:  2017-12-07

Review 9.  Extracellular Vesicles in Non-alcoholic Fatty Liver Disease and Alcoholic Liver Disease.

Authors:  Dongqing Wu; Huaqing Zhu; Hua Wang
Journal:  Front Physiol       Date:  2021-07-14       Impact factor: 4.566

Review 10.  Extracellular vesicles in liver pathobiology: Small particles with big impact.

Authors:  Petra Hirsova; Samar H Ibrahim; Vikas K Verma; Leslie A Morton; Vijay H Shah; Nicholas F LaRusso; Gregory J Gores; Harmeet Malhi
Journal:  Hepatology       Date:  2016-10-20       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.